The Associated Press
COVID-19 vaccines and the return of customers to stores helped push CVS Health well past fourth-quarter earnings expectations.
But the pandemic’s unpredictability is making the drugstore chain and pharmacy benefit manager cautious heading into 2022.
It did not raise a 2022 forecast it laid out in December, and its shares started sliding early Wednesday.
Vaccines that helped boost fourth quarter sales could drop as much as 80% in the new year.
Company leaders also expect a decline in in-store diagnostic testing.
Plus they don’t know if there will be another surge in cases or round of vaccine boosters.
